###begin article-title 0
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease
###end article-title 0
###begin title 1
Objective
###end title 1
###begin p 2
###xml 100 108 <span type="species:ncbi:9606">patients</span>
To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson's disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 382 385 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 394 397 394 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 445 448 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients included were first-time users of the non-ergoline DA ropinirole or pramipexole who had been diagnosed with PD before 2005. Treatment discontinuation was defined as a gap of 180 days or more between two refills of the DA. Non-genetic determinants for discontinuation were studied in the overall population, and genetic determinants [DRD2 141C Ins/Del, DRD2 (CA)n STR, DRD2 TaqIA, DRD3 MscI single nucleotide polymorphism (SNP) and DRD3 MspI SNP] were studied in a subgroup. Cox proportional hazard analysis was used to estimate the hazard ratios (HR) for the discontinuation of non-ergoline DA treatment.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 589 592 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
The study population comprised 90 patients. Apomorphine use was associated with non-ergoline DA discontinuation, although the apomorphine group consisted only of three patients [HR 6.26; 95% confidence interval (CI) 1.85-21.2]. Daily levodopa dosages between 500 and 1000 mg were positively associated with discontinuation (HR 2.31; 95% CI 1.08-4.93). Included in the exploratory pharmacogenetic analysis were 38 patients. The absence of a 15x DRD2 CA repeat allele was significantly related with a decreased discontinuation of non-ergoline treatment (HR 0.23; 95% CI 0.07-0.81). The DRD3 MspI polymorphism showed a non-significant allele dose effect, suggestive of a causal relationship.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 212 220 <span type="species:ncbi:9606">patients</span>
This study identified apomorphine use and levodopa dosages between 500 and 1000 mg as non-genetic and the 15x DRD2 CA repeat allele as genetic determinants for the discontinuation of non-ergoline DA treatment in patients with PD. More research is needed to replicate these findings.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 616 617 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
Long-term treatment with levodopa, which is still considered to be the gold standard for the pharmacotherapeutic management of patients with Parkinson's disease (PD), often leads to motor complications, such as wearing-off and dyskinesias [1]. As a result, dopaminergic therapy with dopamine agonists (DA) has gained popularity as initial therapy in younger patients and as add-on therapy in older individuals. However, it has been demonstrated that in clinical practice over half of patients initiating non-ergoline DA ropinirole and pramipexole therapy have discontinued (51 and 60%, respectively) within 3 years [2].
###end p 11
###begin p 12
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
Remarkably, determinants for the discontinuation of non-ergoline DA therapy are largely unknown. We hypothesize that several non-genetic factors, such as the duration of PD or concurrent drug use, are associated with this discontinuation of non-ergoline DA use. We also suggest that genetic polymorphisms in the genes encoding the dopamine receptor (DR) are associated with this discontinuation. Several polymorphisms in the DR have been identified [3-7], and those in DRD2 and DRD3 could be important determinants because the non-ergoline DA have high binding characteristics for the DRD2 subgroup and a preferential affinity for the DRD3 subgroup.
###end p 12
###begin p 13
The aim of this study was to identify non-genetic determinants for the discontinuation of non-ergoline DA and to perform an exploratory analysis of genetic determinants in genes encoding DRD2 and DRD3.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Setting, study population and data collection
###end title 15
###begin p 16
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:9606">patients</span>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
The setting of this cohort study was the neurology department of a large teaching hospital in Enschede, The Netherlands. Outpatients diagnosed with PD before 2005 who had received a non-ergoline DA (ropinirole or pramipexole) for the first time were included. Prescription data were retrieved from community pharmacies after obtaining the patients' informed consent as described in an earlier publication [2]. The date of the first prescription of the DA was defined as the index date. To ascertain first-time use, we required that the patients had at least 180 days of prescription history for any prescribed drug before the index date. In addition, patients needed to have at least 180 days of prescription data for any medicine after the index date. Thereafter, patients were asked for informed consent in order to obtain saliva for DNA collection and pharmacogenetic analysis. All genotyped patients were of Caucasian ethnicity. The patients included in the genetic analysis were asked in a semi-structured interview by a researcher (MA) if they could recollect any period in which they had discontinued non-ergoline DA treatment and, if so, what was the reason for this discontinuation. The study was approved by the medical ethics committee.
###end p 16
###begin title 17
Endpoint
###end title 17
###begin p 18
###xml 77 85 <span type="species:ncbi:9606">Patients</span>
###xml 256 264 <span type="species:ncbi:9606">Patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
The endpoint of this study was discontinuation of non-ergoline DA treatment. Patients were considered to have discontinued ropinirole or pramipexole treatment when more than 180 days elapsed between two consecutive pharmacy refills of the non-ergoline DA. Patients who persisted with therapy to the end of their observation time were censored on the last day of their follow-up. Consequently, patients who were lost to follow-up (e.g. moved to another place or died) were censored on the last day of their follow-up.
###end p 18
###begin title 19
Determinants
###end title 19
###begin p 20
Non-genetic determinants present at the index date were recorded from the medical charts and extracted from the prescription histories. We investigated gender, age, duration of PD, type of non-ergoline DA treatment, concomitant use of other antiparkinson drugs, daily levodopa dosage, and concomitant use of antipsychotics and antidepressants. The mean dosage of non-ergoline DA during follow-up was also investigated as a determinant for discontinuation.
###end p 20
###begin p 21
###xml 353 354 353 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 365 368 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 393 396 393 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Genetic determinants for discontinuation of non-ergoline DA treatment were studied in the subgroup of patients who gave separate informed consent for genetic testing. Polymorphisms in the DRD2 gene and DRD3 gene were selected based on indications for clinical relevance determined from previous publications: DRD2 141C Ins/Del SNP (rs1799732), DRD2 (CA)n STR, DRD2 TaqIA SNP (rs1800497), DRD3 MscI single nucleotide polymorphism (SNP) (rs6280) and DRD3 MspI SNP (rs4646996) [8].
###end p 21
###begin title 22
Genotyping
###end title 22
###begin p 23
###xml 534 536 534 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aq</italic>
###xml 633 636 633 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 676 679 676 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 981 985 981 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Taq</italic>
###xml 998 999 998 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 999 1000 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Saliva specimens were collected with Oragene-DNA tubes (DNA Genotek, Kanata, ONT, Canada). Polymerase chain reaction analyses were performed under standard conditions on the MyCycler system (Bio-Rad, Veenendaal, The Netherlands). The Hotstart PCR Mastermix was obtained from Qiagen (Hilden, Germany). Genotyping was performed according to the protocol provided by the manufacturers (Invitrogen, Breda, The Netherlands; Promega, Leiden, The Netherlands). Allele frequencies were as follows: for DRD2 141-C, 72% ins, 28% del; for DRD2 TaqIA (C>T), 71% C, 29% T; for DRD2 (CA)n STR, 13% 13x, 11% 14x, 46% 15x, 29% 16x, 1% 17x; for DRD3 MscI (Ser>Gly), 79% Ser, 21% Gly; for DRD3 MspI (A>G), 47% A (absence), 54% G (presence). The allele frequencies were in accordance with those reported in the literature [8]. The genotype frequencies were in Hardy-Weinberg equilibrium, and the genotyping success rate was 100.0%. A linkage disequilibrium was found between DRD2 ins/del and the DRD2 TaqIA genotype (r2 = 0.937).
###end p 23
###begin title 24
Data analysis
###end title 24
###begin p 25
###xml 88 90 88 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> t</italic>
Fisher's exact test was used to test differences in dichotomous variables, and Student's t-test was used for continuous variables. Cox proportional hazard analysis was used to estimate the hazard ratios (HR) for the discontinuation of non-ergoline DA treatment. Cumulative hazards for discontinuation were plotted against the time of follow-up. In the genetic analyses, alleles were combined because of the relative low numbers in the genetic subgroup.
###end p 25
###begin p 26
All analyses were performed using SPSS ver. 12.0 (SPSS, Chicago, IL).
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Description of the cohort
###end title 28
###begin p 29
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 557 559 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> p</italic>
###xml 623 625 623 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> p</italic>
###xml 636 643 636 643 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 643 687 643 687 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Baseline characteristics of the study cohort</p>
###xml 643 687 643 687 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Baseline characteristics of the study cohort</p></caption>
###xml 687 752 687 752 <th xmlns:xlink="http://www.w3.org/1999/xlink">Baseline demographic/clinical characteristics of study population</th>
###xml 772 774 772 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 752 780 752 780 <th xmlns:xlink="http://www.w3.org/1999/xlink">Overall population (<italic>n&#8201;</italic> =&#8201;90)</th>
###xml 807 810 807 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n &#8201;</italic>
###xml 780 815 780 815 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genetic analysis subgroup (<italic>n &#8201;</italic>=&#8201;38)</th>
###xml 815 816 815 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 822 823 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 815 823 815 823 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value<sup>a</sup></th>
###xml 687 823 687 823 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Baseline demographic/clinical characteristics of study population</th><th>Overall population (<italic>n&#8201;</italic> =&#8201;90)</th><th>Genetic analysis subgroup (<italic>n &#8201;</italic>=&#8201;38)</th><th><italic>p</italic> value<sup>a</sup></th></tr>
###xml 687 823 687 823 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Baseline demographic/clinical characteristics of study population</th><th>Overall population (<italic>n&#8201;</italic> =&#8201;90)</th><th>Genetic analysis subgroup (<italic>n &#8201;</italic>=&#8201;38)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead>
###xml 823 834 823 834 <td xmlns:xlink="http://www.w3.org/1999/xlink">Male gender</td>
###xml 834 843 834 843 <td xmlns:xlink="http://www.w3.org/1999/xlink">49 (54.4)</td>
###xml 843 852 843 852 <td xmlns:xlink="http://www.w3.org/1999/xlink">25 (65.8)</td>
###xml 852 857 852 857 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.087</td>
###xml 823 857 823 857 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Male gender</td><td>49 (54.4)</td><td>25 (65.8)</td><td>0.087</td></tr>
###xml 857 886 857 886 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean age in years (SD); range</td>
###xml 886 903 886 903 <td xmlns:xlink="http://www.w3.org/1999/xlink">67.8 (8.7); 48&#8211;91</td>
###xml 903 920 903 920 <td xmlns:xlink="http://www.w3.org/1999/xlink">63.4 (6.9); 49&#8211;78</td>
###xml 920 926 920 926 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 857 926 857 926 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean age in years (SD); range</td><td>67.8 (8.7); 48&#8211;91</td><td>63.4 (6.9); 49&#8211;78</td><td>&lt;0.001</td></tr>
###xml 926 937 926 937 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&lt;65&#160;years</td>
###xml 937 946 937 946 <td xmlns:xlink="http://www.w3.org/1999/xlink">29 (32.2)</td>
###xml 946 955 946 955 <td xmlns:xlink="http://www.w3.org/1999/xlink">21 (55.3)</td>
###xml 955 960 955 960 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.001</td>
###xml 926 960 926 960 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&lt;65&#160;years</td><td>29 (32.2)</td><td>21 (55.3)</td><td>0.001</td></tr>
###xml 960 973 960 971 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;65&#160;years</td>
###xml 973 982 971 980 <td xmlns:xlink="http://www.w3.org/1999/xlink">61 (67.8)</td>
###xml 982 991 980 989 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (44.7)</td>
###xml 991 991 989 989 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 960 991 960 989 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;65&#160;years</td><td>61 (67.8)</td><td>17 (44.7)</td><td/></tr>
###xml 991 1028 989 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean duration of PD in years, (range)</td>
###xml 1028 1039 1026 1037 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.2; 0&#8211;39.3</td>
###xml 1039 1050 1037 1048 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.4; 0&#8211;16.2</td>
###xml 1050 1055 1048 1053 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.022</td>
###xml 991 1055 989 1053 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean duration of PD in years, (range)</td><td>6.2; 0&#8211;39.3</td><td>4.4; 0&#8211;16.2</td><td>0.022</td></tr>
###xml 1055 1065 1053 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&lt;5&#160;years</td>
###xml 1065 1074 1063 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink">47 (52.2)</td>
###xml 1074 1083 1072 1081 <td xmlns:xlink="http://www.w3.org/1999/xlink">21 (55.3)</td>
###xml 1083 1088 1081 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.673</td>
###xml 1055 1088 1053 1086 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&lt;5&#160;years</td><td>47 (52.2)</td><td>21 (55.3)</td><td>0.673</td></tr>
###xml 1088 1100 1086 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;5&#160;years</td>
###xml 1100 1109 1096 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink">43 (47.8)</td>
###xml 1109 1118 1105 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (44.7)</td>
###xml 1118 1118 1114 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1088 1118 1086 1114 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;5&#160;years</td><td>43 (47.8)</td><td>17 (44.7)</td><td/></tr>
###xml 1118 1149 1114 1145 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean follow-up in months; range</td>
###xml 1149 1163 1145 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.7; 0.4&#8211;91.0</td>
###xml 1163 1177 1159 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.0; 0.4&#8211;91.0</td>
###xml 1177 1182 1173 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.288</td>
###xml 1118 1182 1114 1178 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean follow-up in months; range</td><td>28.7; 0.4&#8211;91.0</td><td>32.0; 0.4&#8211;91.0</td><td>0.288</td></tr>
###xml 1182 1221 1178 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink">Non-ergoline dopamine agonist treatment</td>
###xml 1221 1221 1217 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1221 1221 1217 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1221 1221 1217 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1182 1221 1178 1217 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Non-ergoline dopamine agonist treatment</td><td/><td/><td/></tr>
###xml 1221 1233 1217 1229 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Ropinirole</td>
###xml 1233 1242 1229 1238 <td xmlns:xlink="http://www.w3.org/1999/xlink">42 (46.7)</td>
###xml 1242 1251 1238 1247 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1251 1256 1247 1252 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.671</td>
###xml 1221 1256 1217 1252 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Ropinirole</td><td>42 (46.7)</td><td>19 (50.0)</td><td>0.671</td></tr>
###xml 1256 1269 1252 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Pramipexole</td>
###xml 1269 1278 1265 1274 <td xmlns:xlink="http://www.w3.org/1999/xlink">48 (53.3)</td>
###xml 1278 1287 1274 1283 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1287 1287 1283 1283 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1256 1287 1252 1283 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Pramipexole</td><td>48 (53.3)</td><td>19 (50.0)</td><td/></tr>
###xml 1287 1348 1283 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink">Concomitant use of other antiparkinsonian drugs at index date</td>
###xml 1348 1348 1344 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1348 1348 1344 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1348 1348 1344 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1287 1348 1283 1344 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Concomitant use of other antiparkinsonian drugs at index date</td><td/><td/><td/></tr>
###xml 1348 1360 1344 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Amantadine</td>
###xml 1360 1369 1356 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (18.9)</td>
###xml 1369 1378 1365 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (26.3)</td>
###xml 1378 1383 1374 1379 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.173</td>
###xml 1348 1383 1344 1379 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Amantadine</td><td>17 (18.9)</td><td>10 (26.3)</td><td>0.173</td></tr>
###xml 1383 1395 1379 1391 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Selegeline</td>
###xml 1395 1402 1391 1398 <td xmlns:xlink="http://www.w3.org/1999/xlink">7 (7.8)</td>
###xml 1402 1409 1398 1405 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (5.3)</td>
###xml 1409 1414 1405 1410 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.694</td>
###xml 1383 1414 1379 1410 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Selegeline</td><td>7 (7.8)</td><td>2 (5.3)</td><td>0.694</td></tr>
###xml 1414 1427 1410 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Apomorphine</td>
###xml 1427 1434 1423 1430 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (3.3)</td>
###xml 1434 1441 1430 1437 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (2.6)</td>
###xml 1441 1446 1437 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.617</td>
###xml 1414 1446 1410 1442 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Apomorphine</td><td>3 (3.3)</td><td>1 (2.6)</td><td>0.617</td></tr>
###xml 1446 1470 1442 1466 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Other dopamine agonist</td>
###xml 1470 1477 1466 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (1.1)</td>
###xml 1477 1482 1473 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink">0 (0)</td>
###xml 1482 1487 1478 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.000</td>
###xml 1446 1487 1442 1483 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Other dopamine agonist</td><td>1 (1.1)</td><td>0 (0)</td><td>1.000</td></tr>
###xml 1487 1497 1483 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Levodopa</td>
###xml 1497 1506 1493 1502 <td xmlns:xlink="http://www.w3.org/1999/xlink">57 (63.3)</td>
###xml 1506 1515 1502 1511 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1515 1520 1511 1516 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.029</td>
###xml 1487 1520 1483 1516 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Levodopa</td><td>57 (63.3)</td><td>19 (50.0)</td><td>0.029</td></tr>
###xml 1520 1586 1516 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean daily levodopa dosage at index date in milligrams (SD); range</td>
###xml 1586 1605 1582 1601 <td xmlns:xlink="http://www.w3.org/1999/xlink">466 (331); 100&#8211;1804</td>
###xml 1605 1624 1601 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink">422 (280); 149&#8211;1302</td>
###xml 1624 1629 1620 1625 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.485</td>
###xml 1520 1629 1516 1625 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean daily levodopa dosage at index date in milligrams (SD); range</td><td>466 (331); 100&#8211;1804</td><td>422 (280); 149&#8211;1302</td><td>0.485</td></tr>
###xml 1629 1638 1625 1634 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&lt;500&#160;mg</td>
###xml 1638 1647 1634 1643 <td xmlns:xlink="http://www.w3.org/1999/xlink">40 (70.2)</td>
###xml 1647 1656 1643 1652 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (73.7)</td>
###xml 1656 1661 1652 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.906</td>
###xml 1629 1661 1625 1657 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&lt;500&#160;mg</td><td>40 (70.2)</td><td>14 (73.7)</td><td>0.906</td></tr>
###xml 1661 1680 1657 1674 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg</td>
###xml 1680 1689 1674 1683 <td xmlns:xlink="http://www.w3.org/1999/xlink">12 (21.1)</td>
###xml 1689 1697 1683 1691 <td xmlns:xlink="http://www.w3.org/1999/xlink">4 (21.1)</td>
###xml 1697 1697 1691 1691 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1661 1697 1657 1691 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg</td><td>12 (21.1)</td><td>4 (21.1)</td><td/></tr>
###xml 1697 1709 1691 1701 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;1000&#160;mg</td>
###xml 1709 1716 1701 1708 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (8.8)</td>
###xml 1716 1723 1708 1715 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (5.3)</td>
###xml 1723 1723 1715 1715 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1697 1723 1691 1715 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;1000&#160;mg</td><td>5 (8.8)</td><td>1 (5.3)</td><td/></tr>
###xml 1723 1772 1715 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink">Concomitant use of other medication at index date</td>
###xml 1772 1772 1764 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1772 1772 1764 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1772 1772 1764 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1723 1772 1715 1764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Concomitant use of other medication at index date</td><td/><td/><td/></tr>
###xml 1772 1788 1764 1780 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Antipsychotics</td>
###xml 1788 1797 1780 1789 <td xmlns:xlink="http://www.w3.org/1999/xlink">12 (13.3)</td>
###xml 1797 1805 1789 1797 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (13.2)</td>
###xml 1805 1810 1797 1802 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.000</td>
###xml 1772 1810 1764 1802 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Antipsychotics</td><td>12 (13.3)</td><td>5 (13.2)</td><td>1.000</td></tr>
###xml 1810 1827 1802 1819 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;Antidepressants</td>
###xml 1827 1834 1819 1826 <td xmlns:xlink="http://www.w3.org/1999/xlink">6 (6.7)</td>
###xml 1834 1841 1826 1833 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (7.9)</td>
###xml 1841 1846 1833 1838 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.694</td>
###xml 1810 1846 1802 1838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;Antidepressants</td><td>6 (6.7)</td><td>3 (7.9)</td><td>0.694</td></tr>
###xml 1887 1888 1879 1880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1846 1900 1838 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean daily dopamine agonist dosage in DDD<sup>b</sup> (SD); range</td>
###xml 1900 1922 1892 1914 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.17 (1.08); 0.17&#8211;6.64</td>
###xml 1922 1944 1914 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.13 (0.89); 0.18&#8211;3.91</td>
###xml 1944 1949 1936 1941 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.787</td>
###xml 1846 1949 1838 1941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean daily dopamine agonist dosage in DDD<sup>b</sup> (SD); range</td><td>1.17 (1.08); 0.17&#8211;6.64</td><td>1.13 (0.89); 0.18&#8211;3.91</td><td>0.787</td></tr>
###xml 1949 1960 1941 1952 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&lt;0.75 DDD</td>
###xml 1960 1969 1952 1961 <td xmlns:xlink="http://www.w3.org/1999/xlink">41 (45.6)</td>
###xml 1969 1978 1961 1970 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1978 1983 1970 1975 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.273</td>
###xml 1949 1983 1941 1975 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&lt;0.75 DDD</td><td>41 (45.6)</td><td>19 (50.0)</td><td>0.273</td></tr>
###xml 1983 2001 1975 1991 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;0.75&#8211;1.50 DDD</td>
###xml 2001 2010 1991 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink">32 (35.6)</td>
###xml 2010 2019 2000 2009 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (26.3)</td>
###xml 2019 2019 2009 2009 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1983 2019 1975 2009 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;0.75&#8211;1.50 DDD</td><td>32 (35.6)</td><td>10 (26.3)</td><td/></tr>
###xml 2019 2032 2009 2020 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#8805;1.50 DDD</td>
###xml 2032 2041 2020 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (18.9)</td>
###xml 2041 2049 2029 2037 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (23.7)</td>
###xml 2049 2049 2037 2037 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2019 2049 2009 2037 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#8805;1.50 DDD</td><td>17 (18.9)</td><td>9 (23.7)</td><td/></tr>
###xml 823 2049 823 2037 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Male gender</td><td>49 (54.4)</td><td>25 (65.8)</td><td>0.087</td></tr><tr><td>Mean age in years (SD); range</td><td>67.8 (8.7); 48&#8211;91</td><td>63.4 (6.9); 49&#8211;78</td><td>&lt;0.001</td></tr><tr><td>&#8201;&#160;&lt;65&#160;years</td><td>29 (32.2)</td><td>21 (55.3)</td><td>0.001</td></tr><tr><td>&#8201;&#160;&#8805;65&#160;years</td><td>61 (67.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean duration of PD in years, (range)</td><td>6.2; 0&#8211;39.3</td><td>4.4; 0&#8211;16.2</td><td>0.022</td></tr><tr><td>&#8201;&#160;&lt;5&#160;years</td><td>47 (52.2)</td><td>21 (55.3)</td><td>0.673</td></tr><tr><td>&#8201;&#160;&#8805;5&#160;years</td><td>43 (47.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean follow-up in months; range</td><td>28.7; 0.4&#8211;91.0</td><td>32.0; 0.4&#8211;91.0</td><td>0.288</td></tr><tr><td>Non-ergoline dopamine agonist treatment</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Ropinirole</td><td>42 (46.7)</td><td>19 (50.0)</td><td>0.671</td></tr><tr><td>&#8201;&#160;Pramipexole</td><td>48 (53.3)</td><td>19 (50.0)</td><td/></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Amantadine</td><td>17 (18.9)</td><td>10 (26.3)</td><td>0.173</td></tr><tr><td>&#8201;&#160;Selegeline</td><td>7 (7.8)</td><td>2 (5.3)</td><td>0.694</td></tr><tr><td>&#8201;&#160;Apomorphine</td><td>3 (3.3)</td><td>1 (2.6)</td><td>0.617</td></tr><tr><td>&#8201;&#160;Other dopamine agonist</td><td>1 (1.1)</td><td>0 (0)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Levodopa</td><td>57 (63.3)</td><td>19 (50.0)</td><td>0.029</td></tr><tr><td>Mean daily levodopa dosage at index date in milligrams (SD); range</td><td>466 (331); 100&#8211;1804</td><td>422 (280); 149&#8211;1302</td><td>0.485</td></tr><tr><td>&#8201;&#160;&lt;500&#160;mg</td><td>40 (70.2)</td><td>14 (73.7)</td><td>0.906</td></tr><tr><td>&#8201;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg</td><td>12 (21.1)</td><td>4 (21.1)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1000&#160;mg</td><td>5 (8.8)</td><td>1 (5.3)</td><td/></tr><tr><td>Concomitant use of other medication at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Antipsychotics</td><td>12 (13.3)</td><td>5 (13.2)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Antidepressants</td><td>6 (6.7)</td><td>3 (7.9)</td><td>0.694</td></tr><tr><td>Mean daily dopamine agonist dosage in DDD<sup>b</sup> (SD); range</td><td>1.17 (1.08); 0.17&#8211;6.64</td><td>1.13 (0.89); 0.18&#8211;3.91</td><td>0.787</td></tr><tr><td>&#8201;&#160;&lt;0.75 DDD</td><td>41 (45.6)</td><td>19 (50.0)</td><td>0.273</td></tr><tr><td>&#8201;&#160;&#8805;0.75&#8211;1.50 DDD</td><td>32 (35.6)</td><td>10 (26.3)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1.50 DDD</td><td>17 (18.9)</td><td>9 (23.7)</td><td/></tr></tbody>
###xml 687 2049 687 2037 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Baseline demographic/clinical characteristics of study population</th><th>Overall population (<italic>n&#8201;</italic> =&#8201;90)</th><th>Genetic analysis subgroup (<italic>n &#8201;</italic>=&#8201;38)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td>Male gender</td><td>49 (54.4)</td><td>25 (65.8)</td><td>0.087</td></tr><tr><td>Mean age in years (SD); range</td><td>67.8 (8.7); 48&#8211;91</td><td>63.4 (6.9); 49&#8211;78</td><td>&lt;0.001</td></tr><tr><td>&#8201;&#160;&lt;65&#160;years</td><td>29 (32.2)</td><td>21 (55.3)</td><td>0.001</td></tr><tr><td>&#8201;&#160;&#8805;65&#160;years</td><td>61 (67.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean duration of PD in years, (range)</td><td>6.2; 0&#8211;39.3</td><td>4.4; 0&#8211;16.2</td><td>0.022</td></tr><tr><td>&#8201;&#160;&lt;5&#160;years</td><td>47 (52.2)</td><td>21 (55.3)</td><td>0.673</td></tr><tr><td>&#8201;&#160;&#8805;5&#160;years</td><td>43 (47.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean follow-up in months; range</td><td>28.7; 0.4&#8211;91.0</td><td>32.0; 0.4&#8211;91.0</td><td>0.288</td></tr><tr><td>Non-ergoline dopamine agonist treatment</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Ropinirole</td><td>42 (46.7)</td><td>19 (50.0)</td><td>0.671</td></tr><tr><td>&#8201;&#160;Pramipexole</td><td>48 (53.3)</td><td>19 (50.0)</td><td/></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Amantadine</td><td>17 (18.9)</td><td>10 (26.3)</td><td>0.173</td></tr><tr><td>&#8201;&#160;Selegeline</td><td>7 (7.8)</td><td>2 (5.3)</td><td>0.694</td></tr><tr><td>&#8201;&#160;Apomorphine</td><td>3 (3.3)</td><td>1 (2.6)</td><td>0.617</td></tr><tr><td>&#8201;&#160;Other dopamine agonist</td><td>1 (1.1)</td><td>0 (0)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Levodopa</td><td>57 (63.3)</td><td>19 (50.0)</td><td>0.029</td></tr><tr><td>Mean daily levodopa dosage at index date in milligrams (SD); range</td><td>466 (331); 100&#8211;1804</td><td>422 (280); 149&#8211;1302</td><td>0.485</td></tr><tr><td>&#8201;&#160;&lt;500&#160;mg</td><td>40 (70.2)</td><td>14 (73.7)</td><td>0.906</td></tr><tr><td>&#8201;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg</td><td>12 (21.1)</td><td>4 (21.1)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1000&#160;mg</td><td>5 (8.8)</td><td>1 (5.3)</td><td/></tr><tr><td>Concomitant use of other medication at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Antipsychotics</td><td>12 (13.3)</td><td>5 (13.2)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Antidepressants</td><td>6 (6.7)</td><td>3 (7.9)</td><td>0.694</td></tr><tr><td>Mean daily dopamine agonist dosage in DDD<sup>b</sup> (SD); range</td><td>1.17 (1.08); 0.17&#8211;6.64</td><td>1.13 (0.89); 0.18&#8211;3.91</td><td>0.787</td></tr><tr><td>&#8201;&#160;&lt;0.75 DDD</td><td>41 (45.6)</td><td>19 (50.0)</td><td>0.273</td></tr><tr><td>&#8201;&#160;&#8805;0.75&#8211;1.50 DDD</td><td>32 (35.6)</td><td>10 (26.3)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1.50 DDD</td><td>17 (18.9)</td><td>9 (23.7)</td><td/></tr></tbody></table>
###xml 2081 2082 2069 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2049 2144 2037 2132 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis, unless stated otherwise</p>
###xml 2144 2216 2132 2204 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">PD, Parkinson's disease; DDD, defined daily dose; SD, standard deviation</p>
###xml 2216 2217 2204 2205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2217 2218 2205 2206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2399 2400 2387 2388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2216 2440 2204 2428 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><sup>a</sup><italic>p</italic> value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher&#8217;s exact test for dichotomous variables and Student&#8217;s <italic>t</italic>-test for continuous variables were used</p>
###xml 2440 2441 2428 2429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2440 2527 2428 2515 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>b</sup>Mean of entire follow-up period. 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg</p>
###xml 2049 2527 2037 2515 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis, unless stated otherwise</p><p textid="32">PD, Parkinson's disease; DDD, defined daily dose; SD, standard deviation</p><p textid="33"><sup>a</sup><italic>p</italic> value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher&#8217;s exact test for dichotomous variables and Student&#8217;s <italic>t</italic>-test for continuous variables were used</p><p textid="34"><sup>b</sup>Mean of entire follow-up period. 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg</p></table-wrap-foot>
###xml 636 2527 636 2515 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="30">Baseline characteristics of the study cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Baseline demographic/clinical characteristics of study population</th><th>Overall population (<italic>n&#8201;</italic> =&#8201;90)</th><th>Genetic analysis subgroup (<italic>n &#8201;</italic>=&#8201;38)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td>Male gender</td><td>49 (54.4)</td><td>25 (65.8)</td><td>0.087</td></tr><tr><td>Mean age in years (SD); range</td><td>67.8 (8.7); 48&#8211;91</td><td>63.4 (6.9); 49&#8211;78</td><td>&lt;0.001</td></tr><tr><td>&#8201;&#160;&lt;65&#160;years</td><td>29 (32.2)</td><td>21 (55.3)</td><td>0.001</td></tr><tr><td>&#8201;&#160;&#8805;65&#160;years</td><td>61 (67.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean duration of PD in years, (range)</td><td>6.2; 0&#8211;39.3</td><td>4.4; 0&#8211;16.2</td><td>0.022</td></tr><tr><td>&#8201;&#160;&lt;5&#160;years</td><td>47 (52.2)</td><td>21 (55.3)</td><td>0.673</td></tr><tr><td>&#8201;&#160;&#8805;5&#160;years</td><td>43 (47.8)</td><td>17 (44.7)</td><td/></tr><tr><td>Mean follow-up in months; range</td><td>28.7; 0.4&#8211;91.0</td><td>32.0; 0.4&#8211;91.0</td><td>0.288</td></tr><tr><td>Non-ergoline dopamine agonist treatment</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Ropinirole</td><td>42 (46.7)</td><td>19 (50.0)</td><td>0.671</td></tr><tr><td>&#8201;&#160;Pramipexole</td><td>48 (53.3)</td><td>19 (50.0)</td><td/></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Amantadine</td><td>17 (18.9)</td><td>10 (26.3)</td><td>0.173</td></tr><tr><td>&#8201;&#160;Selegeline</td><td>7 (7.8)</td><td>2 (5.3)</td><td>0.694</td></tr><tr><td>&#8201;&#160;Apomorphine</td><td>3 (3.3)</td><td>1 (2.6)</td><td>0.617</td></tr><tr><td>&#8201;&#160;Other dopamine agonist</td><td>1 (1.1)</td><td>0 (0)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Levodopa</td><td>57 (63.3)</td><td>19 (50.0)</td><td>0.029</td></tr><tr><td>Mean daily levodopa dosage at index date in milligrams (SD); range</td><td>466 (331); 100&#8211;1804</td><td>422 (280); 149&#8211;1302</td><td>0.485</td></tr><tr><td>&#8201;&#160;&lt;500&#160;mg</td><td>40 (70.2)</td><td>14 (73.7)</td><td>0.906</td></tr><tr><td>&#8201;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg</td><td>12 (21.1)</td><td>4 (21.1)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1000&#160;mg</td><td>5 (8.8)</td><td>1 (5.3)</td><td/></tr><tr><td>Concomitant use of other medication at index date</td><td/><td/><td/></tr><tr><td>&#8201;&#160;Antipsychotics</td><td>12 (13.3)</td><td>5 (13.2)</td><td>1.000</td></tr><tr><td>&#8201;&#160;Antidepressants</td><td>6 (6.7)</td><td>3 (7.9)</td><td>0.694</td></tr><tr><td>Mean daily dopamine agonist dosage in DDD<sup>b</sup> (SD); range</td><td>1.17 (1.08); 0.17&#8211;6.64</td><td>1.13 (0.89); 0.18&#8211;3.91</td><td>0.787</td></tr><tr><td>&#8201;&#160;&lt;0.75 DDD</td><td>41 (45.6)</td><td>19 (50.0)</td><td>0.273</td></tr><tr><td>&#8201;&#160;&#8805;0.75&#8211;1.50 DDD</td><td>32 (35.6)</td><td>10 (26.3)</td><td/></tr><tr><td>&#8201;&#160;&#8805;1.50 DDD</td><td>17 (18.9)</td><td>9 (23.7)</td><td/></tr></tbody></table><table-wrap-foot><p textid="31">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis, unless stated otherwise</p><p textid="32">PD, Parkinson's disease; DDD, defined daily dose; SD, standard deviation</p><p textid="33"><sup>a</sup><italic>p</italic> value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher&#8217;s exact test for dichotomous variables and Student&#8217;s <italic>t</italic>-test for continuous variables were used</p><p textid="34"><sup>b</sup>Mean of entire follow-up period. 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg</p></table-wrap-foot></table-wrap>
###xml 2527 2533 2515 2521 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 2533 2582 2521 2570 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Flow-chart of inclusion genetic analysis subgroup</p>
###xml 2533 2582 2521 2570 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Flow-chart of inclusion genetic analysis subgroup</p></caption>
###xml 2582 2582 2570 2570 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="228_2009_708_Fig1_HTML" id="MO1"/>
###xml 2527 2582 2515 2570 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="35">Flow-chart of inclusion genetic analysis subgroup</p></caption><graphic position="anchor" xlink:href="228_2009_708_Fig1_HTML" id="MO1"/></fig>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 2233 2241 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the cohort are described in Table 1. The overall study population consisted of 90 patients who were first-time users of a non-ergoline DA treatment; 50% were ropinirole starters and 50% were pramipexole starters. The mean follow-up period was 28.7 months. DNA samples for an exploratory pharmacogenetic analysis were available for 38 patients. The flow-chart of inclusion in the genetic analysis subgroup is presented in Fig. 1. Compared to the total cohort, patients for whom DNA was available were younger (63.4 vs. 69.8 years; p < 0.001) and had a shorter disease duration (4.4 vs. 7.4 years; p = 0.022). Table 1Baseline characteristics of the study cohortBaseline demographic/clinical characteristics of study populationOverall population (n  = 90)Genetic analysis subgroup (n  = 38)p valueaMale gender49 (54.4)25 (65.8)0.087Mean age in years (SD); range67.8 (8.7); 48-9163.4 (6.9); 49-78<0.001  <65 years29 (32.2)21 (55.3)0.001  >/=65 years61 (67.8)17 (44.7)Mean duration of PD in years, (range)6.2; 0-39.34.4; 0-16.20.022  <5 years47 (52.2)21 (55.3)0.673  >/=5 years43 (47.8)17 (44.7)Mean follow-up in months; range28.7; 0.4-91.032.0; 0.4-91.00.288Non-ergoline dopamine agonist treatment  Ropinirole42 (46.7)19 (50.0)0.671  Pramipexole48 (53.3)19 (50.0)Concomitant use of other antiparkinsonian drugs at index date  Amantadine17 (18.9)10 (26.3)0.173  Selegeline7 (7.8)2 (5.3)0.694  Apomorphine3 (3.3)1 (2.6)0.617  Other dopamine agonist1 (1.1)0 (0)1.000  Levodopa57 (63.3)19 (50.0)0.029Mean daily levodopa dosage at index date in milligrams (SD); range466 (331); 100-1804422 (280); 149-13020.485  <500 mg40 (70.2)14 (73.7)0.906  >/=500 mg-1000 mg12 (21.1)4 (21.1)  >/=1000 mg5 (8.8)1 (5.3)Concomitant use of other medication at index date  Antipsychotics12 (13.3)5 (13.2)1.000  Antidepressants6 (6.7)3 (7.9)0.694Mean daily dopamine agonist dosage in DDDb (SD); range1.17 (1.08); 0.17-6.641.13 (0.89); 0.18-3.910.787  <0.75 DDD41 (45.6)19 (50.0)0.273  >/=0.75-1.50 DDD32 (35.6)10 (26.3)  >/=1.50 DDD17 (18.9)9 (23.7)Values are given as the number (n), with the percentage in parenthesis, unless stated otherwisePD, Parkinson's disease; DDD, defined daily dose; SD, standard deviationap value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher's exact test for dichotomous variables and Student's t-test for continuous variables were usedbMean of entire follow-up period. 1 DDD ropinirole = 6.0 mg; 1 DDD pramipexole = 2.5 mgFig. 1Flow-chart of inclusion genetic analysis subgroup
###end p 29
###begin p 30
Baseline characteristics of the study cohort
###end p 30
###begin p 31
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Values are given as the number (n), with the percentage in parenthesis, unless stated otherwise
###end p 31
###begin p 32
PD, Parkinson's disease; DDD, defined daily dose; SD, standard deviation
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
ap value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher's exact test for dichotomous variables and Student's t-test for continuous variables were used
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bMean of entire follow-up period. 1 DDD ropinirole = 6.0 mg; 1 DDD pramipexole = 2.5 mg
###end p 34
###begin p 35
Flow-chart of inclusion genetic analysis subgroup
###end p 35
###begin p 36
###xml 154 162 <span type="species:ncbi:9606">patients</span>
In the overall population, there was a large range in mean daily DA dosage during follow-up: from 0.17 to 6.64 defined daily dosages (DDD). However, most patients used <1.5 DDD (81.1%).
###end p 36
###begin title 37
Discontinuation
###end title 37
###begin p 38
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 727 734 727 734 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 734 829 734 829 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Reported reasons for discontinuation of non-ergoline treatment in the genetic analysis subgroup</p>
###xml 734 829 734 829 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Reported reasons for discontinuation of non-ergoline treatment in the genetic analysis subgroup</p></caption>
###xml 829 892 829 892 <th xmlns:xlink="http://www.w3.org/1999/xlink">Clinical basis for discontinuation of non-ergoline DA treatment</th>
###xml 919 925 919 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;38</italic>
###xml 892 926 892 926 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genetic analysis subgroup (<italic>n&#8201;=&#8201;38</italic>)</th>
###xml 829 926 829 926 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Clinical basis for discontinuation of non-ergoline DA treatment</th><th>Genetic analysis subgroup (<italic>n&#8201;=&#8201;38</italic>)</th></tr>
###xml 829 926 829 926 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Clinical basis for discontinuation of non-ergoline DA treatment</th><th>Genetic analysis subgroup (<italic>n&#8201;=&#8201;38</italic>)</th></tr></thead>
###xml 926 978 926 978 <td xmlns:xlink="http://www.w3.org/1999/xlink">Patients that discontinued non-ergoline DA treatment</td>
###xml 978 987 978 987 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (52.6)</td>
###xml 926 987 926 987 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Patients that discontinued non-ergoline DA treatment</td><td>20 (52.6)</td></tr>
###xml 987 1007 987 1007 <td xmlns:xlink="http://www.w3.org/1999/xlink">Confirmed by patient</td>
###xml 1007 1016 1007 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink">18 (90.0)</td>
###xml 987 1016 987 1016 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Confirmed by patient</td><td>18 (90.0)</td></tr>
###xml 1016 1045 1016 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink">Discontinuation initiated by:</td>
###xml 1045 1045 1045 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1016 1045 1016 1045 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Discontinuation initiated by:</td><td/></tr>
###xml 1045 1057 1045 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;Neurologist</td>
###xml 1057 1067 1057 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink">18 (100.0)</td>
###xml 1045 1067 1045 1067 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;Neurologist</td><td>18 (100.0)</td></tr>
###xml 1067 1094 1067 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reasons for discontinuation</td>
###xml 1094 1094 1094 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1067 1094 1067 1094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Reasons for discontinuation</td><td/></tr>
###xml 1094 1122 1094 1122 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;Lack of sufficient response</td>
###xml 1122 1130 1122 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink">4 (22.2)</td>
###xml 1094 1130 1094 1130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;Lack of sufficient response</td><td>4 (22.2)</td></tr>
###xml 1143 1144 1143 1144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1130 1144 1130 1144 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;Side effects<sup>a</sup></td>
###xml 1144 1152 1144 1152 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (50.0)</td>
###xml 1130 1152 1130 1152 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;Side effects<sup>a</sup></td><td>9 (50.0)</td></tr>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1152 1183 1152 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Excessive daytime sleepiness<sup>a</sup></td>
###xml 1183 1184 1183 1184 <td xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 1152 1184 1152 1184 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Excessive daytime sleepiness<sup>a</sup></td><td>3</td></tr>
###xml 1184 1213 1184 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Hallucinations or psychosis</td>
###xml 1213 1214 1213 1214 <td xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 1184 1214 1184 1214 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Hallucinations or psychosis</td><td>2</td></tr>
###xml 1214 1222 1214 1222 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Nausea</td>
###xml 1222 1223 1222 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1214 1223 1214 1223 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Nausea</td><td>1</td></tr>
###xml 1223 1253 1223 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Lightheadedness or dizziness</td>
###xml 1253 1254 1253 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1223 1254 1223 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Lightheadedness or dizziness</td><td>1</td></tr>
###xml 1272 1273 1272 1273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1254 1273 1254 1273 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Daily sleepiness<sup>a</sup></td>
###xml 1273 1274 1273 1274 <td xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 1254 1274 1254 1274 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Daily sleepiness<sup>a</sup></td><td>3</td></tr>
###xml 1290 1291 1290 1291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1274 1291 1274 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Hypersexuality<sup>a</sup></td>
###xml 1291 1292 1291 1292 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1274 1292 1274 1292 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Hypersexuality<sup>a</sup></td><td>1</td></tr>
###xml 1317 1318 1317 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1292 1318 1292 1318 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Dopaminergic drug abuse<sup>a</sup></td>
###xml 1318 1319 1318 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1292 1319 1292 1319 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Dopaminergic drug abuse<sup>a</sup></td><td>1</td></tr>
###xml 1319 1330 1319 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Diarrhoea</td>
###xml 1330 1331 1330 1331 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1319 1331 1319 1331 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Diarrhoea</td><td>1</td></tr>
###xml 1331 1339 1331 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Eczema</td>
###xml 1339 1340 1339 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1331 1340 1331 1340 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Eczema</td><td>1</td></tr>
###xml 1340 1370 1340 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;Patient can not recall reason</td>
###xml 1370 1378 1370 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (27.8)</td>
###xml 1340 1378 1340 1378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;Patient can not recall reason</td><td>5 (27.8)</td></tr>
###xml 926 1378 926 1378 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Patients that discontinued non-ergoline DA treatment</td><td>20 (52.6)</td></tr><tr><td>Confirmed by patient</td><td>18 (90.0)</td></tr><tr><td>Discontinuation initiated by:</td><td/></tr><tr><td>&#8201;Neurologist</td><td>18 (100.0)</td></tr><tr><td>Reasons for discontinuation</td><td/></tr><tr><td>&#8201;Lack of sufficient response</td><td>4 (22.2)</td></tr><tr><td>&#8201;Side effects<sup>a</sup></td><td>9 (50.0)</td></tr><tr><td>&#160;&#160;Excessive daytime sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hallucinations or psychosis</td><td>2</td></tr><tr><td>&#160;&#160;Nausea</td><td>1</td></tr><tr><td>&#160;&#160;Lightheadedness or dizziness</td><td>1</td></tr><tr><td>&#160;&#160;Daily sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hypersexuality<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Dopaminergic drug abuse<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Diarrhoea</td><td>1</td></tr><tr><td>&#160;&#160;Eczema</td><td>1</td></tr><tr><td>&#8201;Patient can not recall reason</td><td>5 (27.8)</td></tr></tbody>
###xml 829 1378 829 1378 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Clinical basis for discontinuation of non-ergoline DA treatment</th><th>Genetic analysis subgroup (<italic>n&#8201;=&#8201;38</italic>)</th></tr></thead><tbody><tr><td>Patients that discontinued non-ergoline DA treatment</td><td>20 (52.6)</td></tr><tr><td>Confirmed by patient</td><td>18 (90.0)</td></tr><tr><td>Discontinuation initiated by:</td><td/></tr><tr><td>&#8201;Neurologist</td><td>18 (100.0)</td></tr><tr><td>Reasons for discontinuation</td><td/></tr><tr><td>&#8201;Lack of sufficient response</td><td>4 (22.2)</td></tr><tr><td>&#8201;Side effects<sup>a</sup></td><td>9 (50.0)</td></tr><tr><td>&#160;&#160;Excessive daytime sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hallucinations or psychosis</td><td>2</td></tr><tr><td>&#160;&#160;Nausea</td><td>1</td></tr><tr><td>&#160;&#160;Lightheadedness or dizziness</td><td>1</td></tr><tr><td>&#160;&#160;Daily sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hypersexuality<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Dopaminergic drug abuse<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Diarrhoea</td><td>1</td></tr><tr><td>&#160;&#160;Eczema</td><td>1</td></tr><tr><td>&#8201;Patient can not recall reason</td><td>5 (27.8)</td></tr></tbody></table>
###xml 1410 1411 1410 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1378 1448 1378 1448 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis</p>
###xml 1448 1468 1448 1468 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">DA, Dopamine agonist</p>
###xml 1468 1469 1468 1469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1468 1509 1468 1509 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><sup>a</sup>One patient reported three side effects.</p>
###xml 1378 1509 1378 1509 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis</p><p textid="41">DA, Dopamine agonist</p><p textid="42"><sup>a</sup>One patient reported three side effects.</p></table-wrap-foot>
###xml 727 1509 727 1509 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="39">Reported reasons for discontinuation of non-ergoline treatment in the genetic analysis subgroup</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical basis for discontinuation of non-ergoline DA treatment</th><th>Genetic analysis subgroup (<italic>n&#8201;=&#8201;38</italic>)</th></tr></thead><tbody><tr><td>Patients that discontinued non-ergoline DA treatment</td><td>20 (52.6)</td></tr><tr><td>Confirmed by patient</td><td>18 (90.0)</td></tr><tr><td>Discontinuation initiated by:</td><td/></tr><tr><td>&#8201;Neurologist</td><td>18 (100.0)</td></tr><tr><td>Reasons for discontinuation</td><td/></tr><tr><td>&#8201;Lack of sufficient response</td><td>4 (22.2)</td></tr><tr><td>&#8201;Side effects<sup>a</sup></td><td>9 (50.0)</td></tr><tr><td>&#160;&#160;Excessive daytime sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hallucinations or psychosis</td><td>2</td></tr><tr><td>&#160;&#160;Nausea</td><td>1</td></tr><tr><td>&#160;&#160;Lightheadedness or dizziness</td><td>1</td></tr><tr><td>&#160;&#160;Daily sleepiness<sup>a</sup></td><td>3</td></tr><tr><td>&#160;&#160;Hypersexuality<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Dopaminergic drug abuse<sup>a</sup></td><td>1</td></tr><tr><td>&#160;&#160;Diarrhoea</td><td>1</td></tr><tr><td>&#160;&#160;Eczema</td><td>1</td></tr><tr><td>&#8201;Patient can not recall reason</td><td>5 (27.8)</td></tr></tbody></table><table-wrap-foot><p textid="40">Values are given as the number (<italic>n</italic>), with the percentage in parenthesis</p><p textid="41">DA, Dopamine agonist</p><p textid="42"><sup>a</sup>One patient reported three side effects.</p></table-wrap-foot></table-wrap>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 926 934 <span type="species:ncbi:9606">Patients</span>
###xml 1341 1348 <span type="species:ncbi:9606">Patient</span>
###xml 1473 1480 <span type="species:ncbi:9606">patient</span>
Of the patients in our study who started on non-ergoline DA treatment, 35.6, 51.1 and 55.6% discontinued this therapy after 1, 3 and 5 years, respectively. Of the patients in the subgroup for pharmacogenetic analysis, 31.6, 47.4 and 52.6% discontinued non-ergoline DA treatment after 1, 3 and 5 years, respectively. Treatment discontinuation was confirmed by 18 of the 20 patients in the genetic subgroup. In all cases, discontinuation was initiated by the neurologist and were based on insufficient response (four patients, 22.2%) and side effects (nine patients, 50.0%). Five patients (27.8%) could not recall the reason of discontinuation. The side effects that were the basis for discontinuation are summarized in Table 2. Table 2Reported reasons for discontinuation of non-ergoline treatment in the genetic analysis subgroupClinical basis for discontinuation of non-ergoline DA treatmentGenetic analysis subgroup (n = 38)Patients that discontinued non-ergoline DA treatment20 (52.6)Confirmed by patient18 (90.0)Discontinuation initiated by: Neurologist18 (100.0)Reasons for discontinuation Lack of sufficient response4 (22.2) Side effectsa9 (50.0)  Excessive daytime sleepinessa3  Hallucinations or psychosis2  Nausea1  Lightheadedness or dizziness1  Daily sleepinessa3  Hypersexualitya1  Dopaminergic drug abusea1  Diarrhoea1  Eczema1 Patient can not recall reason5 (27.8)Values are given as the number (n), with the percentage in parenthesisDA, Dopamine agonistaOne patient reported three side effects.
###end p 38
###begin p 39
Reported reasons for discontinuation of non-ergoline treatment in the genetic analysis subgroup
###end p 39
###begin p 40
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Values are given as the number (n), with the percentage in parenthesis
###end p 40
###begin p 41
DA, Dopamine agonist
###end p 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 5 12 <span type="species:ncbi:9606">patient</span>
aOne patient reported three side effects.
###end p 42
###begin title 43
Non-genetic determinants associated with non-ergoline DA discontinuation
###end title 43
###begin p 44
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 743 750 739 746 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 750 834 746 830 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Hazard ratios for discontinuation of non-ergoline DA treatment in overall population</p>
###xml 750 834 746 830 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Hazard ratios for discontinuation of non-ergoline DA treatment in overall population</p></caption>
###xml 834 870 830 866 <th xmlns:xlink="http://www.w3.org/1999/xlink">Demographic/clinical characteristics</th>
###xml 880 882 876 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 870 887 866 883 <th xmlns:xlink="http://www.w3.org/1999/xlink">Crude HR, <italic>n&#8201;</italic> =&#8201;90</th>
###xml 834 887 830 883 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Demographic/clinical characteristics</th><th>Crude HR, <italic>n&#8201;</italic> =&#8201;90</th></tr>
###xml 834 887 830 883 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Demographic/clinical characteristics</th><th>Crude HR, <italic>n&#8201;</italic> =&#8201;90</th></tr></thead>
###xml 887 893 883 889 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gender</td>
###xml 893 893 889 889 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 887 893 883 889 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gender</td><td/></tr>
###xml 893 900 889 896 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Male</td>
###xml 900 909 896 905 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 893 909 889 905 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Male</td><td>Reference</td></tr>
###xml 909 918 905 914 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Female</td>
###xml 918 934 914 930 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.75 (0.43&#8211;1.31)</td>
###xml 909 934 905 930 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Female</td><td>0.75 (0.43&#8211;1.31)</td></tr>
###xml 934 937 930 933 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age</td>
###xml 937 937 933 933 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 934 937 930 933 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age</td><td/></tr>
###xml 937 949 933 945 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&lt;65&#160;years</td>
###xml 949 958 945 954 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 937 958 933 954 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&lt;65&#160;years</td><td>Reference</td></tr>
###xml 958 972 954 966 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;65&#160;years</td>
###xml 972 988 966 982 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.04 (0.57&#8211;1.91)</td>
###xml 958 988 954 982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;65&#160;years</td><td>1.04 (0.57&#8211;1.91)</td></tr>
###xml 988 1002 982 996 <td xmlns:xlink="http://www.w3.org/1999/xlink">Duration of PD</td>
###xml 1002 1002 996 996 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 988 1002 982 996 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Duration of PD</td><td/></tr>
###xml 1002 1013 996 1007 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&lt;5&#160;years</td>
###xml 1013 1022 1007 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1002 1022 996 1016 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&lt;5&#160;years</td><td>Reference</td></tr>
###xml 1022 1035 1016 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;5&#160;years</td>
###xml 1035 1051 1027 1043 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.81 (0.46&#8211;1.41)</td>
###xml 1022 1051 1016 1043 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;5&#160;years</td><td>0.81 (0.46&#8211;1.41)</td></tr>
###xml 1051 1060 1043 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink">Treatment</td>
###xml 1060 1060 1052 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1051 1060 1043 1052 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Treatment</td><td/></tr>
###xml 1060 1073 1052 1065 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Ropinirole</td>
###xml 1073 1082 1065 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1060 1082 1052 1074 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Ropinirole</td><td>Reference</td></tr>
###xml 1082 1096 1074 1088 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Pramipexole</td>
###xml 1096 1112 1088 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.15 (0.66&#8211;2.02)</td>
###xml 1082 1112 1074 1104 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Pramipexole</td><td>1.15 (0.66&#8211;2.02)</td></tr>
###xml 1177 1178 1169 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1112 1178 1104 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink">Concomitant use of other antiparkinsonian drugs at index date (%)<sup>a</sup></td>
###xml 1178 1178 1170 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1112 1178 1104 1170 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Concomitant use of other antiparkinsonian drugs at index date (%)<sup>a</sup></td><td/></tr>
###xml 1178 1191 1170 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Amantadine</td>
###xml 1191 1207 1183 1199 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.76 (0.36&#8211;1.62)</td>
###xml 1178 1207 1170 1199 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Amantadine</td><td>0.76 (0.36&#8211;1.62)</td></tr>
###xml 1207 1220 1199 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Selegeline</td>
###xml 1220 1236 1212 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.97 (0.35&#8211;2.71)</td>
###xml 1207 1236 1199 1228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Selegeline</td><td>0.97 (0.35&#8211;2.71)</td></tr>
###xml 1250 1251 1242 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1236 1251 1228 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Apomorphine<sup>b</sup></td>
###xml 1251 1267 1243 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.26 (1.85&#8211;21.2)</td>
###xml 1236 1267 1228 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Apomorphine<sup>b</sup></td><td>6.26 (1.85&#8211;21.2)</td></tr>
###xml 1267 1292 1259 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Other dopamine agonist</td>
###xml 1292 1304 1284 1296 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.05 (0&#8211;702)</td>
###xml 1267 1304 1259 1296 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Other dopamine agonist</td><td>0.05 (0&#8211;702)</td></tr>
###xml 1304 1315 1296 1307 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Levodopa</td>
###xml 1315 1331 1307 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.26 (0.70&#8211;2.28)</td>
###xml 1304 1331 1296 1323 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Levodopa</td><td>1.26 (0.70&#8211;2.28)</td></tr>
###xml 1331 1366 1323 1358 <td xmlns:xlink="http://www.w3.org/1999/xlink">Daily levodopa dosage at index date</td>
###xml 1366 1366 1358 1358 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1331 1366 1323 1358 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Daily levodopa dosage at index date</td><td/></tr>
###xml 1366 1376 1358 1368 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&lt;500&#160;mg</td>
###xml 1376 1385 1368 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1366 1385 1358 1377 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&lt;500&#160;mg</td><td>Reference</td></tr>
###xml 1405 1406 1395 1396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1385 1406 1377 1396 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg<sup>b</sup></td>
###xml 1406 1422 1396 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.31 (1.08&#8211;4.93)</td>
###xml 1385 1422 1377 1412 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg<sup>b</sup></td><td>2.31 (1.08&#8211;4.93)</td></tr>
###xml 1422 1435 1412 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;1000&#160;mg</td>
###xml 1435 1451 1423 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.59 (0.47&#8211;5.37)</td>
###xml 1422 1451 1412 1439 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;1000&#160;mg</td><td>1.59 (0.47&#8211;5.37)</td></tr>
###xml 1504 1505 1492 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1451 1505 1439 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink">Concomitant use of other medication at index date (%)<sup>a</sup></td>
###xml 1505 1505 1493 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1451 1505 1439 1493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Concomitant use of other medication at index date (%)<sup>a</sup></td><td/></tr>
###xml 1505 1522 1493 1510 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Antipsychotics</td>
###xml 1522 1538 1510 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.62 (0.25&#8211;1.57)</td>
###xml 1505 1538 1493 1526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Antipsychotics</td><td>0.62 (0.25&#8211;1.57)</td></tr>
###xml 1538 1556 1526 1544 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Antidepressants</td>
###xml 1556 1572 1544 1560 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.68 (0.21&#8211;2.18)</td>
###xml 1538 1572 1526 1560 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Antidepressants</td><td>0.68 (0.21&#8211;2.18)</td></tr>
###xml 1602 1603 1590 1591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1572 1603 1560 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink">Daily dopamine agonist dosage <sup>c</sup></td>
###xml 1603 1603 1591 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1572 1603 1560 1591 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Daily dopamine agonist dosage <sup>c</sup></td><td/></tr>
###xml 1603 1615 1591 1603 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&lt;0.75 DDD</td>
###xml 1615 1624 1603 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1603 1624 1591 1612 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&lt;0.75 DDD</td><td>Reference</td></tr>
###xml 1643 1644 1629 1630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1624 1644 1612 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;0.75&#8211;1.50 DDD<sup>b</sup></td>
###xml 1644 1660 1630 1646 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.39 (0.20&#8211;0.75)</td>
###xml 1624 1660 1612 1646 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;0.75&#8211;1.50 DDD<sup>b</sup></td><td>0.39 (0.20&#8211;0.75)</td></tr>
###xml 1674 1675 1658 1659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1660 1675 1646 1659 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;&#8805;1.50 DDD<sup>b</sup></td>
###xml 1675 1691 1659 1675 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.39 (0.17&#8211;0.88)</td>
###xml 1660 1691 1646 1675 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;&#8805;1.50 DDD<sup>b</sup></td><td>0.39 (0.17&#8211;0.88)</td></tr>
###xml 887 1691 883 1675 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Gender</td><td/></tr><tr><td>&#8201;&#160;&#160;Male</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Female</td><td>0.75 (0.43&#8211;1.31)</td></tr><tr><td>Age</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;65&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;65&#160;years</td><td>1.04 (0.57&#8211;1.91)</td></tr><tr><td>Duration of PD</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;5&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;5&#160;years</td><td>0.81 (0.46&#8211;1.41)</td></tr><tr><td>Treatment</td><td/></tr><tr><td>&#8201;&#160;&#160;Ropinirole</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Pramipexole</td><td>1.15 (0.66&#8211;2.02)</td></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Amantadine</td><td>0.76 (0.36&#8211;1.62)</td></tr><tr><td>&#8201;&#160;&#160;Selegeline</td><td>0.97 (0.35&#8211;2.71)</td></tr><tr><td>&#8201;&#160;&#160;Apomorphine<sup>b</sup></td><td>6.26 (1.85&#8211;21.2)</td></tr><tr><td>&#8201;&#160;&#160;Other dopamine agonist</td><td>0.05 (0&#8211;702)</td></tr><tr><td>&#8201;&#160;&#160;Levodopa</td><td>1.26 (0.70&#8211;2.28)</td></tr><tr><td>Daily levodopa dosage at index date</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;500&#160;mg</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg<sup>b</sup></td><td>2.31 (1.08&#8211;4.93)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1000&#160;mg</td><td>1.59 (0.47&#8211;5.37)</td></tr><tr><td>Concomitant use of other medication at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Antipsychotics</td><td>0.62 (0.25&#8211;1.57)</td></tr><tr><td>&#8201;&#160;&#160;Antidepressants</td><td>0.68 (0.21&#8211;2.18)</td></tr><tr><td>Daily dopamine agonist dosage <sup>c</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;0.75 DDD</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;0.75&#8211;1.50 DDD<sup>b</sup></td><td>0.39 (0.20&#8211;0.75)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1.50 DDD<sup>b</sup></td><td>0.39 (0.17&#8211;0.88)</td></tr></tbody>
###xml 834 1691 830 1675 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Demographic/clinical characteristics</th><th>Crude HR, <italic>n&#8201;</italic> =&#8201;90</th></tr></thead><tbody><tr><td>Gender</td><td/></tr><tr><td>&#8201;&#160;&#160;Male</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Female</td><td>0.75 (0.43&#8211;1.31)</td></tr><tr><td>Age</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;65&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;65&#160;years</td><td>1.04 (0.57&#8211;1.91)</td></tr><tr><td>Duration of PD</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;5&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;5&#160;years</td><td>0.81 (0.46&#8211;1.41)</td></tr><tr><td>Treatment</td><td/></tr><tr><td>&#8201;&#160;&#160;Ropinirole</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Pramipexole</td><td>1.15 (0.66&#8211;2.02)</td></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Amantadine</td><td>0.76 (0.36&#8211;1.62)</td></tr><tr><td>&#8201;&#160;&#160;Selegeline</td><td>0.97 (0.35&#8211;2.71)</td></tr><tr><td>&#8201;&#160;&#160;Apomorphine<sup>b</sup></td><td>6.26 (1.85&#8211;21.2)</td></tr><tr><td>&#8201;&#160;&#160;Other dopamine agonist</td><td>0.05 (0&#8211;702)</td></tr><tr><td>&#8201;&#160;&#160;Levodopa</td><td>1.26 (0.70&#8211;2.28)</td></tr><tr><td>Daily levodopa dosage at index date</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;500&#160;mg</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg<sup>b</sup></td><td>2.31 (1.08&#8211;4.93)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1000&#160;mg</td><td>1.59 (0.47&#8211;5.37)</td></tr><tr><td>Concomitant use of other medication at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Antipsychotics</td><td>0.62 (0.25&#8211;1.57)</td></tr><tr><td>&#8201;&#160;&#160;Antidepressants</td><td>0.68 (0.21&#8211;2.18)</td></tr><tr><td>Daily dopamine agonist dosage <sup>c</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;0.75 DDD</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;0.75&#8211;1.50 DDD<sup>b</sup></td><td>0.39 (0.20&#8211;0.75)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1.50 DDD<sup>b</sup></td><td>0.39 (0.17&#8211;0.88)</td></tr></tbody></table>
###xml 1691 1786 1675 1770 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesis</p>
###xml 1786 1787 1770 1771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1786 1820 1770 1804 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><sup>a</sup> Presence vs. absence (Reference)</p>
###xml 1820 1821 1804 1805 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1820 1876 1804 1860 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><sup>b</sup>Factors associated with non-ergoline DA discontinuation</p>
###xml 1876 1877 1860 1861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1876 2066 1860 2050 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49"><sup>c</sup>Mean of entire follow-up period: 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)</p>
###xml 1691 2066 1675 2050 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesis</p><p textid="47"><sup>a</sup> Presence vs. absence (Reference)</p><p textid="48"><sup>b</sup>Factors associated with non-ergoline DA discontinuation</p><p textid="49"><sup>c</sup>Mean of entire follow-up period: 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)</p></table-wrap-foot>
###xml 743 2066 739 2050 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="45">Hazard ratios for discontinuation of non-ergoline DA treatment in overall population</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Demographic/clinical characteristics</th><th>Crude HR, <italic>n&#8201;</italic> =&#8201;90</th></tr></thead><tbody><tr><td>Gender</td><td/></tr><tr><td>&#8201;&#160;&#160;Male</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Female</td><td>0.75 (0.43&#8211;1.31)</td></tr><tr><td>Age</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;65&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;65&#160;years</td><td>1.04 (0.57&#8211;1.91)</td></tr><tr><td>Duration of PD</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;5&#160;years</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;5&#160;years</td><td>0.81 (0.46&#8211;1.41)</td></tr><tr><td>Treatment</td><td/></tr><tr><td>&#8201;&#160;&#160;Ropinirole</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;Pramipexole</td><td>1.15 (0.66&#8211;2.02)</td></tr><tr><td>Concomitant use of other antiparkinsonian drugs at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Amantadine</td><td>0.76 (0.36&#8211;1.62)</td></tr><tr><td>&#8201;&#160;&#160;Selegeline</td><td>0.97 (0.35&#8211;2.71)</td></tr><tr><td>&#8201;&#160;&#160;Apomorphine<sup>b</sup></td><td>6.26 (1.85&#8211;21.2)</td></tr><tr><td>&#8201;&#160;&#160;Other dopamine agonist</td><td>0.05 (0&#8211;702)</td></tr><tr><td>&#8201;&#160;&#160;Levodopa</td><td>1.26 (0.70&#8211;2.28)</td></tr><tr><td>Daily levodopa dosage at index date</td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;500&#160;mg</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;500&#160;mg&#8211;1000&#160;mg<sup>b</sup></td><td>2.31 (1.08&#8211;4.93)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1000&#160;mg</td><td>1.59 (0.47&#8211;5.37)</td></tr><tr><td>Concomitant use of other medication at index date (%)<sup>a</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;Antipsychotics</td><td>0.62 (0.25&#8211;1.57)</td></tr><tr><td>&#8201;&#160;&#160;Antidepressants</td><td>0.68 (0.21&#8211;2.18)</td></tr><tr><td>Daily dopamine agonist dosage <sup>c</sup></td><td/></tr><tr><td>&#8201;&#160;&#160;&lt;0.75 DDD</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;&#8805;0.75&#8211;1.50 DDD<sup>b</sup></td><td>0.39 (0.20&#8211;0.75)</td></tr><tr><td>&#8201;&#160;&#160;&#8805;1.50 DDD<sup>b</sup></td><td>0.39 (0.17&#8211;0.88)</td></tr></tbody></table><table-wrap-foot><p textid="46">Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesis</p><p textid="47"><sup>a</sup> Presence vs. absence (Reference)</p><p textid="48"><sup>b</sup>Factors associated with non-ergoline DA discontinuation</p><p textid="49"><sup>c</sup>Mean of entire follow-up period: 1 DDD ropinirole&#8201;=&#8201;6.0&#160;mg; 1 DDD pramipexole&#8201;=&#8201;2.5&#160;mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)</p></table-wrap-foot></table-wrap>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
The results of the Cox regression analysis are presented in Table 3. All 90 patients were included in this analysis. Apomorphine use was associated with non-ergoline DA discontinuation [HR 6.26; 95% confidence interval (CI) 1.85-21.2]. However, the apomorphine group consisted only of three patients. The use of levodopa resulted in conflicting data in that its actual use was not associated with discontinuation, but within the levodopa users, dosages between 500 and 1000 mg were positively associated with discontinuation (HR 2.31; 95% CI 1.08-4.93). Higher dosages of non-ergoline DA were associated with less treatment discontinuation over time (HR for >/=0.75-1.50 DDD 0.39; 95% CI 0.20-0.75; HR for >/=1.50 DDD 0.39; 95% CI 0.17-0.88). Table 3Hazard ratios for discontinuation of non-ergoline DA treatment in overall populationDemographic/clinical characteristicsCrude HR, n  = 90Gender   MaleReference   Female0.75 (0.43-1.31)Age   <65 yearsReference   >/=65 years1.04 (0.57-1.91)Duration of PD   <5 yearsReference   >/=5 years0.81 (0.46-1.41)Treatment   RopiniroleReference   Pramipexole1.15 (0.66-2.02)Concomitant use of other antiparkinsonian drugs at index date (%)a   Amantadine0.76 (0.36-1.62)   Selegeline0.97 (0.35-2.71)   Apomorphineb6.26 (1.85-21.2)   Other dopamine agonist0.05 (0-702)   Levodopa1.26 (0.70-2.28)Daily levodopa dosage at index date   <500 mgReference   >/=500 mg-1000 mgb2.31 (1.08-4.93)   >/=1000 mg1.59 (0.47-5.37)Concomitant use of other medication at index date (%)a   Antipsychotics0.62 (0.25-1.57)   Antidepressants0.68 (0.21-2.18)Daily dopamine agonist dosage c   <0.75 DDDReference   >/=0.75-1.50 DDDb0.39 (0.20-0.75)   >/=1.50 DDDb0.39 (0.17-0.88)Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesisa Presence vs. absence (Reference)bFactors associated with non-ergoline DA discontinuationcMean of entire follow-up period: 1 DDD ropinirole = 6.0 mg; 1 DDD pramipexole = 2.5 mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)
###end p 44
###begin p 45
Hazard ratios for discontinuation of non-ergoline DA treatment in overall population
###end p 45
###begin p 46
Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesis
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
a Presence vs. absence (Reference)
###end p 47
###begin p 48
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bFactors associated with non-ergoline DA discontinuation
###end p 48
###begin p 49
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cMean of entire follow-up period: 1 DDD ropinirole = 6.0 mg; 1 DDD pramipexole = 2.5 mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)
###end p 49
###begin title 50
Genetic determinants associated with non-ergoline DA discontinuation
###end title 50
###begin p 51
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 455 458 455 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 816 823 816 823 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 823 914 823 914 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Hazard ratios for discontinuation of non-ergoline DA treatment in genetic analysis subgroup</p>
###xml 823 914 823 914 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Hazard ratios for discontinuation of non-ergoline DA treatment in genetic analysis subgroup</p></caption>
###xml 914 922 914 922 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</th>
###xml 949 951 949 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 922 958 922 958 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genetic analysis subgroup (<italic>n&#8201;</italic> =&#8201;38)<sup>a</sup></th>
###xml 958 974 958 974 <th xmlns:xlink="http://www.w3.org/1999/xlink">Crude HR (95%CI)</th>
###xml 914 974 914 974 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Genotype</th><th>Genetic analysis subgroup (<italic>n&#8201;</italic> =&#8201;38)<sup>a</sup></th><th>Crude HR (95%CI)</th></tr>
###xml 914 974 914 974 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Genotype</th><th>Genetic analysis subgroup (<italic>n&#8201;</italic> =&#8201;38)<sup>a</sup></th><th>Crude HR (95%CI)</th></tr></thead>
###xml 974 992 974 992 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DRD2 141-C ins/del</td>
###xml 974 992 974 992 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">DRD2 141-C ins/del</td></tr>
###xml 992 1002 992 1002 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;Ins/Ins</td>
###xml 1002 1011 1002 1011 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (52.6)</td>
###xml 1011 1020 1011 1020 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 992 1020 992 1020 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;Ins/Ins</td><td>20 (52.6)</td><td>Reference</td></tr>
###xml 1020 1040 1020 1040 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;Ins/Del + Del/Del</td>
###xml 1040 1049 1040 1049 <td xmlns:xlink="http://www.w3.org/1999/xlink">18 (47.4)</td>
###xml 1049 1065 1049 1065 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.00 (0.42&#8211;2.42)</td>
###xml 1020 1065 1020 1065 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;Ins/Del + Del/Del</td><td>18 (47.4)</td><td>1.00 (0.42&#8211;2.42)</td></tr>
###xml 1069 1073 1069 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Taq</italic>
###xml 1065 1081 1065 1081 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DRD2<italic> Taq</italic>1A (C&gt;T)</td>
###xml 1065 1081 1065 1081 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">DRD2<italic> Taq</italic>1A (C&gt;T)</td></tr>
###xml 1081 1087 1081 1087 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;C/C</td>
###xml 1087 1096 1087 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1096 1105 1096 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1081 1105 1081 1105 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;C/C</td><td>19 (50.0)</td><td>Reference</td></tr>
###xml 1105 1117 1105 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;C/T + T/T</td>
###xml 1117 1126 1117 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (50.0)</td>
###xml 1126 1142 1126 1142 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84 (0.35&#8211;2.04)</td>
###xml 1105 1142 1105 1142 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;C/T + T/T</td><td>19 (50.0)</td><td>0.84 (0.35&#8211;2.04)</td></tr>
###xml 1142 1156 1142 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DRD2 (CA)n STR</td>
###xml 1142 1156 1142 1156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">DRD2 (CA)n STR</td></tr>
###xml 1156 1169 1156 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;15&#215; allele</td>
###xml 1169 1178 1169 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink">26 (68.4)</td>
###xml 1178 1187 1178 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1156 1187 1156 1187 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;15&#215; allele</td><td>26 (68.4)</td><td>Reference</td></tr>
###xml 1203 1204 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1187 1204 1187 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;No 15&#215; allele<sup>b</sup></td>
###xml 1204 1213 1204 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink">12 (31.6)</td>
###xml 1213 1229 1213 1229 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.23 (0.07&#8211;0.81)</td>
###xml 1187 1229 1187 1229 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;No 15&#215; allele<sup>b</sup></td><td>12 (31.6)</td><td>0.23 (0.07&#8211;0.81)</td></tr>
###xml 1233 1237 1233 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Msc</italic>
###xml 1229 1248 1229 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DRD3<italic> Msc</italic>I (Ser&gt;Gly)</td>
###xml 1229 1248 1229 1248 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">DRD3<italic> Msc</italic>I (Ser&gt;Gly)</td></tr>
###xml 1248 1258 1248 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8201;&#160;&#160;Ser/Ser</td>
###xml 1258 1267 1258 1267 <td xmlns:xlink="http://www.w3.org/1999/xlink">24 (63.2)</td>
###xml 1267 1276 1267 1276 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1248 1276 1248 1276 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#8201;&#160;&#160;Ser/Ser</td><td>24 (63.2)</td><td>Reference</td></tr>
###xml 1276 1296 1276 1296 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8201;Ser/Gly + Gly/Gly</td>
###xml 1296 1305 1296 1305 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (36.8)</td>
###xml 1305 1321 1305 1321 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.79 (0.31&#8211;1.98)</td>
###xml 1276 1321 1276 1321 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8201;Ser/Gly + Gly/Gly</td><td>14 (36.8)</td><td>0.79 (0.31&#8211;1.98)</td></tr>
###xml 1325 1329 1325 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Msp</italic>
###xml 1321 1377 1321 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DRD3<italic> Msp</italic>I (A&gt;G) (absence &gt; presence of restriction site)</td>
###xml 1321 1377 1321 1377 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">DRD3<italic> Msp</italic>I (A&gt;G) (absence &gt; presence of restriction site)</td></tr>
###xml 1377 1382 1377 1382 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#8201;A/A</td>
###xml 1382 1390 1382 1390 <td xmlns:xlink="http://www.w3.org/1999/xlink">8 (21.1)</td>
###xml 1390 1399 1390 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink">Reference</td>
###xml 1377 1399 1377 1399 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#8201;A/A</td><td>8 (21.1)</td><td>Reference</td></tr>
###xml 1399 1410 1399 1410 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;A/G + G/G</td>
###xml 1410 1419 1410 1419 <td xmlns:xlink="http://www.w3.org/1999/xlink">30 (78.9)</td>
###xml 1419 1435 1419 1435 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.09 (0.61&#8211;7.17)</td>
###xml 1399 1435 1399 1435 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;A/G + G/G</td><td>30 (78.9)</td><td>2.09 (0.61&#8211;7.17)</td></tr>
###xml 974 1435 974 1435 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="3">DRD2 141-C ins/del</td></tr><tr><td>&#160;&#160;&#8201;Ins/Ins</td><td>20 (52.6)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ins/Del + Del/Del</td><td>18 (47.4)</td><td>1.00 (0.42&#8211;2.42)</td></tr><tr><td colspan="3">DRD2<italic> Taq</italic>1A (C&gt;T)</td></tr><tr><td>&#160;&#160;&#8201;C/C</td><td>19 (50.0)</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;C/T + T/T</td><td>19 (50.0)</td><td>0.84 (0.35&#8211;2.04)</td></tr><tr><td colspan="3">DRD2 (CA)n STR</td></tr><tr><td>&#160;&#160;&#8201;15&#215; allele</td><td>26 (68.4)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;No 15&#215; allele<sup>b</sup></td><td>12 (31.6)</td><td>0.23 (0.07&#8211;0.81)</td></tr><tr><td colspan="3">DRD3<italic> Msc</italic>I (Ser&gt;Gly)</td></tr><tr><td>&#8201;&#160;&#160;Ser/Ser</td><td>24 (63.2)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ser/Gly + Gly/Gly</td><td>14 (36.8)</td><td>0.79 (0.31&#8211;1.98)</td></tr><tr><td colspan="3">DRD3<italic> Msp</italic>I (A&gt;G) (absence &gt; presence of restriction site)</td></tr><tr><td>&#160;&#8201;A/A</td><td>8 (21.1)</td><td>Reference</td></tr><tr><td>&#160;&#160;A/G + G/G</td><td>30 (78.9)</td><td>2.09 (0.61&#8211;7.17)</td></tr></tbody>
###xml 914 1435 914 1435 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Genetic analysis subgroup (<italic>n&#8201;</italic> =&#8201;38)<sup>a</sup></th><th>Crude HR (95%CI)</th></tr></thead><tbody><tr><td colspan="3">DRD2 141-C ins/del</td></tr><tr><td>&#160;&#160;&#8201;Ins/Ins</td><td>20 (52.6)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ins/Del + Del/Del</td><td>18 (47.4)</td><td>1.00 (0.42&#8211;2.42)</td></tr><tr><td colspan="3">DRD2<italic> Taq</italic>1A (C&gt;T)</td></tr><tr><td>&#160;&#160;&#8201;C/C</td><td>19 (50.0)</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;C/T + T/T</td><td>19 (50.0)</td><td>0.84 (0.35&#8211;2.04)</td></tr><tr><td colspan="3">DRD2 (CA)n STR</td></tr><tr><td>&#160;&#160;&#8201;15&#215; allele</td><td>26 (68.4)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;No 15&#215; allele<sup>b</sup></td><td>12 (31.6)</td><td>0.23 (0.07&#8211;0.81)</td></tr><tr><td colspan="3">DRD3<italic> Msc</italic>I (Ser&gt;Gly)</td></tr><tr><td>&#8201;&#160;&#160;Ser/Ser</td><td>24 (63.2)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ser/Gly + Gly/Gly</td><td>14 (36.8)</td><td>0.79 (0.31&#8211;1.98)</td></tr><tr><td colspan="3">DRD3<italic> Msp</italic>I (A&gt;G) (absence &gt; presence of restriction site)</td></tr><tr><td>&#160;&#8201;A/A</td><td>8 (21.1)</td><td>Reference</td></tr><tr><td>&#160;&#160;A/G + G/G</td><td>30 (78.9)</td><td>2.09 (0.61&#8211;7.17)</td></tr></tbody></table>
###xml 1435 1436 1435 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1468 1469 1468 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1435 1518 1435 1518 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53"><sup>a</sup>Values are given as the number (<italic>n</italic>) of patients, with the percentage in parenthesis</p>
###xml 1518 1519 1518 1519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1518 1633 1518 1633 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><sup>b</sup>The absence of a 15&#215; DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment</p>
###xml 1435 1633 1435 1633 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53"><sup>a</sup>Values are given as the number (<italic>n</italic>) of patients, with the percentage in parenthesis</p><p textid="54"><sup>b</sup>The absence of a 15&#215; DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment</p></table-wrap-foot>
###xml 816 1633 816 1633 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="52">Hazard ratios for discontinuation of non-ergoline DA treatment in genetic analysis subgroup</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Genetic analysis subgroup (<italic>n&#8201;</italic> =&#8201;38)<sup>a</sup></th><th>Crude HR (95%CI)</th></tr></thead><tbody><tr><td colspan="3">DRD2 141-C ins/del</td></tr><tr><td>&#160;&#160;&#8201;Ins/Ins</td><td>20 (52.6)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ins/Del + Del/Del</td><td>18 (47.4)</td><td>1.00 (0.42&#8211;2.42)</td></tr><tr><td colspan="3">DRD2<italic> Taq</italic>1A (C&gt;T)</td></tr><tr><td>&#160;&#160;&#8201;C/C</td><td>19 (50.0)</td><td>Reference</td></tr><tr><td>&#8201;&#160;&#160;C/T + T/T</td><td>19 (50.0)</td><td>0.84 (0.35&#8211;2.04)</td></tr><tr><td colspan="3">DRD2 (CA)n STR</td></tr><tr><td>&#160;&#160;&#8201;15&#215; allele</td><td>26 (68.4)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;No 15&#215; allele<sup>b</sup></td><td>12 (31.6)</td><td>0.23 (0.07&#8211;0.81)</td></tr><tr><td colspan="3">DRD3<italic> Msc</italic>I (Ser&gt;Gly)</td></tr><tr><td>&#8201;&#160;&#160;Ser/Ser</td><td>24 (63.2)</td><td>Reference</td></tr><tr><td>&#160;&#160;&#8201;Ser/Gly + Gly/Gly</td><td>14 (36.8)</td><td>0.79 (0.31&#8211;1.98)</td></tr><tr><td colspan="3">DRD3<italic> Msp</italic>I (A&gt;G) (absence &gt; presence of restriction site)</td></tr><tr><td>&#160;&#8201;A/A</td><td>8 (21.1)</td><td>Reference</td></tr><tr><td>&#160;&#160;A/G + G/G</td><td>30 (78.9)</td><td>2.09 (0.61&#8211;7.17)</td></tr></tbody></table><table-wrap-foot><p textid="53"><sup>a</sup>Values are given as the number (<italic>n</italic>) of patients, with the percentage in parenthesis</p><p textid="54"><sup>b</sup>The absence of a 15&#215; DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment</p></table-wrap-foot></table-wrap>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">Patients</span>
###xml 1474 1482 <span type="species:ncbi:9606">patients</span>
The results of the Cox regression analysis of genetic determinants, carried out on 38 patients, are presented in Table 4. The absence of a 15x DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment (HR 0.23; 95% CI 0.07-0.81). Patients with the DRD3 MspI G allele (presence of MspI restriction site) had a non-significant twofold higher risk of non-ergoline DA treatment discontinuation (95% CI 0.61-7.17). The DRD3 MspI polymorphism showed an allele dose effect (increase in risk per G allele), which is suggestive of a causal relationship with discontinuation (A/A: ref; A/G: HR 1.56; 95% CI 0.42-5.77; G/G: HR 3.50; 95% CI 0.91-13.4). No other statistically significant associations between genetic polymorphisms and non-ergoline DA treatment discontinuation were detected. Table 4Hazard ratios for discontinuation of non-ergoline DA treatment in genetic analysis subgroupGenotypeGenetic analysis subgroup (n  = 38)aCrude HR (95%CI)DRD2 141-C ins/del   Ins/Ins20 (52.6)Reference   Ins/Del + Del/Del18 (47.4)1.00 (0.42-2.42)DRD2 Taq1A (C>T)   C/C19 (50.0)Reference   C/T + T/T19 (50.0)0.84 (0.35-2.04)DRD2 (CA)n STR   15x allele26 (68.4)Reference   No 15x alleleb12 (31.6)0.23 (0.07-0.81)DRD3 MscI (Ser>Gly)   Ser/Ser24 (63.2)Reference   Ser/Gly + Gly/Gly14 (36.8)0.79 (0.31-1.98)DRD3 MspI (A>G) (absence > presence of restriction site)  A/A8 (21.1)Reference  A/G + G/G30 (78.9)2.09 (0.61-7.17)aValues are given as the number (n) of patients, with the percentage in parenthesisbThe absence of a 15x DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment
###end p 51
###begin p 52
Hazard ratios for discontinuation of non-ergoline DA treatment in genetic analysis subgroup
###end p 52
###begin p 53
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 33 34 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
aValues are given as the number (n) of patients, with the percentage in parenthesis
###end p 53
###begin p 54
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bThe absence of a 15x DRD2 CA repeat allele was related to a decreased discontinuation of non-ergoline DA treatment
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 363 364 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
This study identified non-genetic and genetic determinants for discontinuation of the non-ergoline DA ropinirole and pramipexole in PD. Non-genetic determinants that were associated with discontinuation were apomorphine use, levodopa dosage, and the dosage of non-ergoline DA during follow-up. In an exploratory pharmacogenetic analysis, we identified a DRD2 (CA)n repeat polymorphism that was associated with non-ergoline DA discontinuation.
###end p 56
###begin p 57
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
Apomorphine use was associated with a sixtime higher risk of discontinuation. Apomorphine is a potent DA and is used in patients with severe on-off fluctuations. As other, less potent dopaminergic drugs can be discontinued with the initiation of apomorphine therapy, it is not surprising that apomorphine use is associated with non-ergoline DA treatment discontinuation. More than half of the patients included in this study used levodopa when starting non-ergoline DA treatment. One might expect that higher levodopa dosages have a higher risk of dopaminergic side effects, often resulting in the discontinuation of other dopaminergic treatment. This is in line with our findings. The use of levodopa itself was not associated with non-ergoline DA discontinuation, but within the levodopa users, dosages between 500 and 1000 mg were positively associated with non-ergoline DA discontinuation. However, as levodopa dosages >1000 mg were not associated with non-ergoline DA discontinuation, this result may have been an artefact due to the relatively small numbers of patients that used >1000 mg levodopa per day.
###end p 57
###begin p 58
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Higher dosages of non-ergoline DA itself were associated with a reduced chance of treatment discontinuation. This can be explained by the fact that the dosage of these drugs is slowly increased in order to minimize adverse events and by the fact that most patients discontinued in the first months after treatment initiation [9]. Thus, this association is a marker for early discontinuation.
###end p 58
###begin p 59
###xml 346 347 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 520 523 520 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 772 775 772 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 908 911 908 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 1068 1072 1068 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MspI</italic>
###xml 1237 1240 1237 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 1300 1301 1300 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1303 1305 1303 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1461 1464 1461 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 1554 1556 1554 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1682 1685 1682 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 1438 1446 <span type="species:ncbi:9606">patients</span>
We hypothesized that genetic polymorphisms in the genes encoding the DR, specifically in DRD2 and DRD3, could be associated with discontinuation of DA use. Indeed, our data show interesting genetic results. The absence of a 15x DRD2 CA repeat allele was associated with a decreased risk of non-ergoline DA treatment discontinuation. The DRD2 (CA)n polymorphism is located in a non-coding region of the DRD2 gene, but the precise functional consequence of this polymorphism for the DRD2 protein remains unclear. The DRD3 MspI polymorphism showed an allele dose effect (increase in the risk of treatment discontinuation per G allele), which is suggestive of a causal relationship. The consequence of this polymorphism on DRD3 functionality remains to be unraveled. The DRD3 MspI polymorphism is located in an intron, suggesting no direct influence of the polymorphism on DRD3 protein function, and is near the MscI polymorphism. However, we found no linkage disequilibrium between these two polymorphisms. It may be that the non-significant association between the DRD3 MspI polymorphism and non-ergoline DA treatment discontinuation is indicative of other polymorphisms not studied in this gene region. Although we expected that the DRD3 MscI Gly polymorphism would lead to increased agonist binding [7, 10], we did not notice an association between this polymorphism and non-ergoline DA discontinuation. Wang and colleagues found that PD patients with the DRD2 TaqIA polymorphism who received levodopa had a higher risk of developing motor fluctuations [11]. Again, we did not find an effect of this polymorphism on DA discontinuation. Our finding may not be surprising as the DRD2 TaqIA polymorphism is located in a kinase gene, denoted the ankyrin repeat and kinase domain containing 1 (ANKK1), which is located downstream of the DRD2 gene. It is therefore unlikely that this polymorphism alters DRD2 activity directly.
###end p 59
###begin p 60
###xml 1314 1315 1314 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
Several remarks should be made with respect to the methodology used. In this study, use of the non-ergoline DA ropinirole and pramipexole was combined in order to improve statistical power. This can be justified by the fact that both ropinirole and pramipexole are DRD2 agonists with a preferential affinity for the DRD3 subgroup. The choice of the endpoint of this study, discontinuation of non-ergoline DA treatment, which encompasses both efficacy and tolerability, is also open to discussion. Since discontinuation related to insufficient efficacy and to intolerability may be mechanistically different, ideally, a stratified analysis on separate endpoints efficacy and tolerability should be performed. However, this could not be done because the reasons for discontinuation in the overall population were not known and because the population in the genetic analysis was too small for subgroup analysis. Moreover, the baseline characteristics in the genetic analysis subgroup differed from those of the overall study population due to the fact that there was a time gap of nearly 2 years between the selection of the overall population and receiving informed consent from patients for the pharmacogenetic analysis. Fortunately, the allele frequencies were in accordance with those reported in the literature [8]. We did not correct for multiple testing as the aim of the genetic subgroup study was to perform an exploratory analysis of genetic determinants. Positive associations should therefore be interpreted with caution. Finally, we included outpatients from only one hospital. Therefore, the results could have been biased by the prescribing patterns of a few clinicians.
###end p 60
###begin p 61
The study reported here is the first to investigate determinants for the discontinuation of non-ergoline DA therapy, including pharmacogenetic determinants. Ideally, knowledge of these determinants will enable clinicians to predict an individual's response.
###end p 61
###begin p 62
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 236 239 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
In conclusion, we have identified non-genetic (apomorphine use and daily levodopa dosages between 500 and 1000 mg) and genetic determinants [DRD2 (CA)n repeat polymorphism] for the discontinuation of non-ergoline DA treatment. The DRD3 MspI polymorphism also showed a non-significant allele dose effect with non-ergoline DA treatment discontinuation, which is suggestive of a causal relationship. Confirmation of these data is warranted.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
We wish to thank all community pharmacists who contributed to this study.
###end p 64
###begin p 65
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Competing interests</bold>
Competing interests Jeroen van Vugt's salary is fully covered by Medisch Spectrum Twente. He has received consultancy and speaker fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Teva Pharma and ApotheekZorg. The other authors have nothing to disclose.
###end p 65
###begin p 66
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
###end article-title 68
###begin article-title 69
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials
###end article-title 69
###begin article-title 70
Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
###end article-title 70
###begin article-title 71
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
###end article-title 71
###begin article-title 72
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study
###end article-title 72
###begin article-title 73
A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder
###end article-title 73
###begin article-title 74
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor
###end article-title 74
###begin article-title 75
Pharmacogenetics of antiparkinsonian drug treatment: a systematic review
###end article-title 75
###begin article-title 76
Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease
###end article-title 76
###begin article-title 77
###xml 83 88 <span type="species:ncbi:9606">human</span>
Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system
###end article-title 77
###begin article-title 78
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD
###end article-title 78
###begin title 79
Abbreviations
###end title 79
###begin p 80
Dopamine agonist
###end p 80
###begin p 81
Dopamine receptor
###end p 81
###begin p 82
Parkinson's disease
###end p 82

